康希諾生物(6185.HK)收漲15%創上市新高 市值首度突破200億至218億港元
格隆匯3月4日丨康希諾生物(6185.HK)今日明顯上漲,在尾盤直線拉昇下,最終收漲14.92%報97.8港元,成交2.22億港元,最新總市值突破200億至218億港元。該股今日盤中創歷史新高價98港元,年內累漲幅度高達66%。康希諾生物是一家致力於研發、生產與銷售的創新型疫苗企業。習近平今日強調,要推進疫苗研發和產業化鏈條有機銜接,加快建立以企業為主體、產學研相結合的疫苗研發和產業化體系,建立國家疫苗儲備制度,為有可能出現的常態化防控工作做好周全準備。中國疫苗行業協會(CAV)此前發佈消息稱,截至2月6日,有17家會員單位正在開展新冠肺炎病毒疫苗的研製工作,科研人員分別採用滅活疫苗、亞單位疫苗、病毒載體疫苗、核酸疫苗等不同技術路徑,加班加點進行攻關,其中17家會員裏就包括康希諾生物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.